title: Improvement of disability and akinesia of patients with Parkinson's disease by intravenous iron substitution.
abstract: Akinetic crises are one of the problems arising in patients with Parkinson's disease in particular after long term treatment with levo-dihydroxyphenylalanine (L-DOPA). They are characterized by severe disability to move. Increasing dosages of L-DOPA and decarboxylase or monoaminooxidase inhibitors do not improve these symptoms. Intravenously applied iron in the form of a ferri-ferro-complex exhibits a considerable benefit for all patients treated so far. They regained a remarkable mobility. Their disability score dropped from up to 90 percent down to 30 percent. The effect is dosage-dependent, and withdrawal of iron will lead again to akinetic crises.
mesh_terms: D015083:2,3-Diketogulonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D000496:Alloxan / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009068:Movement; D010300:Parkinson Disease / Q000503:physiopathology* / Q000628:therapy; D013400:Sugar Acids / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D005290:Ferric Compounds; D013400:Sugar Acids; D015083:2,3-Diketogulonic Acid; C008747:oxyferriscorbone; D000496:Alloxan